Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib;=
AgomAb Therapeutics NV ADR
AgomAb Therapeutics NV ADR AGMB | 0.00 |
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability --
-- Study initiation on track, with first participants expected to be dosed in the second half of 2026 --